Clinical Trial Update: Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing sorafenib to 5-fluorouracil/mitomycin for metastatic hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Mitomycin-C (mitomycin C)
• Nexavar (Sorafenib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED